GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (LTS:0K1R) » Definitions » ROE % Adjusted to Book Value

Viridian Therapeutics (LTS:0K1R) ROE % Adjusted to Book Value : -14.27% (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Viridian Therapeutics ROE % Adjusted to Book Value?

Viridian Therapeutics's ROE % for the quarter that ended in Dec. 2024 was -46.25%. Viridian Therapeutics's PB Ratio for the quarter that ended in Dec. 2024 was 3.24. Viridian Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -14.27%.


Viridian Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Viridian Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics ROE % Adjusted to Book Value Chart

Viridian Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -5.31 -9.19 -11.52 -14.96

Viridian Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.95 -12.98 -19.01 -14.42 -14.27

Competitive Comparison of Viridian Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Viridian Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viridian Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's ROE % Adjusted to Book Value falls into.


;
;

Viridian Therapeutics ROE % Adjusted to Book Value Calculation

Viridian Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-48.48% / 3.24
=-14.96%

Viridian Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-46.25% / 3.24
=-14.27%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viridian Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Viridian Therapeutics Business Description

Traded in Other Exchanges
Address
221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Viridian Therapeutics Headlines

No Headlines